Дата: 12-04-2025, 08:47
The know-how has been extensively studied in section 1 and part 2 clinical trials and has been proven to lessen gluten-induced intestinal mucosal harm as well as enhance signs in clinical trials. Investigators at the Massachusetts General Hospital are conducting a double-blind, placebo-controlled trial to determine the safety and efficacy of Ritlecitinib to stop gluten-induced signs in celiac illness patients. Future drug therapies are at present in development with the hope of reducing the burden of dwelling with celiac illness and enhancing lengthy-time period health outcomes. Dr. Nielsen Fernandez-Becker, head of the Celiac Disease Program at Stanford University, is collaborating with Protagonist Therapeutics to test the security and efficacy of the drug PTG-one hundred in patients with celiac disease. Currently, the one accessible treatment for a affected person with celiac disease is a strict gluten-free weight loss program. Topas has recently concluded a phase 2a clinical trial testing TPM502 for the treatment of celiac illness. Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying remedies for autoimmune and inflammatory diseases. Topas is growing antigen-specific proprietary nanoparticles, referred to as TPCs (Topas Particle Conjugates), which harness the natural mechanisms of the liver to promote antigen-specific immune tolerance without broadly suppressing the immune response.